COST-EFFECTIVENESS OF SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON BETA-1A IN PORTUGAL BASED ON THE FINDINGS OF COCHRANE COLLABORATION REVIEW OF FIRST-LINE TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

被引：0
|
作者：
Silverio, N. [1 ]
Sequeira, L. [1 ]
Meletiche, D. [2 ]
机构：
[1] Merck SA, Alges, Portugal
[2] EMD Serono, Rockland, ME USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.897
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND43
引用
收藏
页码：A398 / A398
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF OCRELIZUMAB IN FIRST-LINE TREATMENT OF HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CHILE
    Vasquez, E.
    Lasalvia, P.
    Rozas, M.
    Gejman, C.
    VALUE IN HEALTH, 2023, 26 (06) : S85 - S86
  • [22] COST-UTILITY ANA LYSIS OF INTRAMUSCULAR INTERFERON BETA-1B VERSUS SUBCUTANEOUS INTERFERON BETA-1B AND BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA
    Ordonez, J.
    Delgado, A.
    VALUE IN HEALTH, 2016, 19 (03) : A63 - A63
  • [23] Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients
    Rudick, R. A.
    Kappos, L.
    Kinkel, R.
    Clanet, M.
    Phillips, J. T.
    Herndon, R. M.
    Sandrock, A. W.
    Munschauer, F. E., III
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (03) : 353 - 360
  • [24] The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Hua, Le H.
    Hersh, Carrie M.
    Morten, Peter
    Kusel, Jeanette
    Lin, Feng
    Cave, Julie
    Varga, Stefan
    Herrera, Vivian
    Ko, John J.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (04): : 490 - +
  • [25] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS SUBCUTANEOUS INTERFERON BETA-1A FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Wandstrat, T.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [26] Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
    Goldberg, Lawrence D.
    Edwards, Natalie C.
    Fincher, Contessa
    Doan, Quan V.
    Al-Sabbagh, Ahmad
    Meletiche, Dennis M.
    JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (07): : 543 - 555
  • [27] COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY
    Nuijten, M. J.
    Mittendorf, T.
    Jaecker, A.
    Osowski, U.
    VALUE IN HEALTH, 2008, 11 (06) : A602 - A602
  • [28] Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis
    Fisher, E.
    Nakamura, K.
    Lee, J-C
    You, X.
    Sperling, B.
    Rudick, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (05) : 668 - 676
  • [29] Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
    Centonze, Diego
    Iannazzo, Sergio
    Santoni, Laura
    Saleri, Cecilia
    Puma, Elisa
    Giuliani, Luigi
    Canonico, Pier Luigi
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2018, 19 (01) : 47 - 52
  • [30] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A IN ITALIAN RELAPSING REMITTING MULTIPLE SCLEROSIS MANAGEMENT
    Iannazzo, S.
    Santoni, L.
    Saleri, C.
    Puma, E.
    Vestri, G.
    Giuliani, L.
    Canonico, P. L.
    Centonze, D.
    VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
12345